Posted by Michael Wonder on 16 Jan 2018
Centrexion Therapeutics announces fast track designation granted by FDA to CNTX-4975 for treatment of knee osteoarthritis pain
16 January 2018 - Centrexion Therapeutics today announced that the U.S. FDA has granted fast track designation to CNTX-4975 for the treatment of pain associated with knee osteoarthritis.
CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.
CNTX-4975 is Phase 3 ready for the treatment of two chronic pain conditions: osteoarthritis pain of the knee and pain associated with Morton’s neuroma, a rare, painful foot condition. The FDA previously granted CNTX-4975 orphan drug designation and fast track designation for the treatment of Morton's neuroma pain. In the Phase 2b TRIUMPH clinical trial, treatment with CNTX-4975 resulted in one of the largest reductions of pain associated with knee osteoarthritis reported in any placebo controlled clinical trial.
